UNSPSC 51343000: Antiviral pyridines

Antiviral drugs made from compounds with a six membered aromatic ring containing nitrogen.

UNSPSC 51343000 Antiviral pyridines (Class) shows minimal alignment with actual state and local procurement activity. The code nominally describes a specific chemical class of antivirals, yet recent opportunities tagged to this code soliciting naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs do not fall within antiviral pyridine scope. State and local buyers post opportunities under this code inconsistently or erroneously; the taxonomic designation does not reflect what is actually being procured in the field. This mismatch signals either a data-quality issue in how opportunities are tagged or a code definition that does not align with real procurement patterns for antiviral products in state and local government.

The issuing bodies posting opportunities under this code include county health agencies (Seminole County, Florida), state health authorities (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local jurisdictions across multiple states including Oregon). Geographic activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026, estimated contract value $700,000), and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, serving multiple state and local agencies). The Texas HHS RFI on direct-to-manufacturer prescriptions (response deadline April 3, 2026) represents early-stage procurement planning. Given the code-to-opportunity mismatch, pursue this code with caution; verify issuing-body tagging practices before investing in response development.